The global radiotherapy market is witnessing significant growth, driven by the alarming rise in cancer cases worldwide and the development of advanced radiotherapy treatments. According to a recent report by MarketsandMarkets, the market’s revenue was estimated to be $6.9 billion in 2023 and is projected to reach $8.8 billion by 2028, exhibiting a compound annual growth rate (CAGR) of 5.0%.

The market’s growth is attributed to several factors, including the rapid increase in cancer cases globally, new developments in radiotherapy treatment such as adaptive radiotherapy, and growing awareness about the advantages of proton therapy for cancer treatment. Additionally, increasing investments in oncology research activities, geographical expansion of radiotherapy device manufacturers, and improving healthcare infrastructure in developing countries are likely to support the market’s growth.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=567

The external beam radiotherapy segment is expected to dominate the market, capturing the largest share in 2023. This segment’s dominance is primarily due to the reduced risk of radiation exposure and increased precision and accuracy in tumor targeting compared to other radiotherapy techniques. Moreover, continuous technological advancements, such as MRI-guided linear accelerators (MRI-LINAC), particle therapy, and rising research activities in the field of radiation oncology using proton therapy systems, are likely to drive the growth of this segment further.

Hospitals are predicted to be the key end-users of radiotherapy systems, driven by government initiatives to upgrade hospital facilities with advanced radiotherapy devices, collaborations between cancer hospitals and radiotherapy device manufacturers, and the increasing number of cancer patients undergoing radiotherapy treatment procedures in hospitals.

Geographically, the Asia-Pacific region is expected to register the highest growth rate during the forecast period. This growth is fueled by the increasing cancer patient pool, improving healthcare infrastructure, and the implementation of supportive government initiatives in several countries, including India and China. Other factors contributing to the region’s growth include the rising geriatric population, growing incidence of cancer, rising acceptance of radiotherapy procedures and devices, increasing medical tourism, and the entry of major market players into Asia-Pacific countries.

Key players in the radiotherapy market include Siemens Healthineers AG (Germany), Varian Medical Systems, Inc. (US), Elekta (Sweden), Accuray Incorporated (US), IBA (Belgium), ViewRay Technologies, Inc. (US), Hitachi Ltd. (Japan), iCAD, Inc. (US), and IsoRay, Inc. (US), among others.

Recent developments in the market include Accuray Incorporated receiving approval for its Tomo C radiation therapy system from the Chinese National Medical Products Administration (NMPA) in October 2023, and IBA’s partnership with the Apollo Proton Cancer Centre (APCC) in India in July 2023 to provide training to oncologists on proton beam therapy.

With the rising burden of cancer cases worldwide and the continuous advancements in radiotherapy technologies, the radiotherapy market is poised for robust growth, offering promising opportunities for both established players and new entrants in the coming years.

The global temperature management systems market is heating up, projected to rise from $3.0 billion in 2023 to $3.9 billion by 2028 at a compound annual growth rate (CAGR) of 4.9%. This growth is fueled by several key drivers, including the increasing prevalence of chronic and infectious diseases, the rising number of surgical procedures, and the growing number of hypothermia cases worldwide.

Patient warming systems are expected to dominate the temperature management systems market, driven by the need to prevent inadvertent perioperative hypothermia and reduce surgical-site infections, hospital stays, and costs per patient. The perioperative care segment will see the highest growth, propelled by technological advancements, product innovations, and strategic partnerships between market players and hospitals.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=141546773

Geographically, North America currently leads the temperature management systems market, buoyed by significant government and private investments to meet the growing demand for advanced medical solutions. However, the Asia-Pacific region presents promising opportunities for market expansion, driven by developing healthcare infrastructure and increasing awareness of temperature management systems.

While the high cost of intravascular temperature management systems and lack of awareness in developing countries pose challenges, the market is ripe for growth opportunities. Key players, such as 3M Company, GE Healthcare, Dragerwerk AG & Co. KGaA, Ecolab, and Asahi-kasei Corporation, are actively pursuing strategies like product launches, acquisitions, and distribution agreements to strengthen their market positions.

Recent developments in the industry include Dragerwerk AG & Co. KGaA’s launch of the FDA-cleared Babyroo TN300 open warmer, Asahi-kasei Corporation’s distribution agreement with BrainCool for temperature management solutions, and ICU Medical’s acquisition of Smiths Medical, bolstering its infusion therapy portfolio.

3M Company (US)

3M company offers products under four operating business segment i.e. Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. It offers temperature management solutions through its Health Care division. The Health Care Business Group serves markets that include Food Safety, Health Information Systems, Medical Solutions, Oral Care, Separation and Purification Sciences, and Other Health Care. Temperature management systems are offered through the Medical Solutions segment.  The company has operations in the US, the Asia Pacific, Europe, the Middle East and Africa (EMEA), Latin America, and Canada. Some of its major subsidiaries include 3M Australia Pty. Ltd., 3M Health Information Systems, Inc. (US), 3M China Limited, and 3M United Kingdom plc (UK). Therefore in December 2022, The company was a named defendant in approximately 5,258 lawsuits in the United States and one Canadian putative class action with a single named plaintiff, alleging that the Bair Hugger patient warming system caused surgical-site infections.

Asahi-kasei Corporation (Japan)

Asahi Kasei is a diversified manufacturer with operations in four business segments—Material, Homes, Healthcare, and Others. The Healthcare business is further segmented into Pharmaceuticals, Medical Care, and Acute Critical Care. ZOLL Medical is a subsidiary of Asahi Kasei Corporation through which company offers the wide range of temperature management systems. ZOLL Medical takes care of the company’s Healthcare business. The company develops and markets medical devices and software solutions to aid in the advancement of emergency care and increase clinical and operational efficiencies..  For Instance, In July 2023, The company signed an agreement with BrainCool, a medical device company specializing in temperature management solutions, for the exclusive distribution of the BrainCool System/IQool System and the IQool System Pads in the US and key markets in Europe. The companies are working toward expanding distribution to select markets in Asia.

As the demand for temperature management systems continues to rise, driven by an aging population, increasing surgical volumes, and advancements in medical technology, the market is poised for sustained growth, offering significant opportunities for established players and newcomers alike.

The softgel capsules industry is experiencing a significant upswing, fueled by a combination of factors that are reshaping the future of ingestible product delivery. At the forefront of this growth is the increasing demand for precise and efficient drug delivery systems, driven by advancements in pharmaceutical and nutraceutical formulations.

Softgel capsules offer a myriad of benefits that have captured the attention of consumers and manufacturers alike. These versatile capsules provide enhanced bioavailability, ensuring that active ingredients are readily absorbed by the body, leading to faster and more efficient delivery. Additionally, they offer accurate dosage control, a crucial factor in pharmaceuticals and supplements where precise dosing is paramount.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=238329912

Furthermore, the rising consumer preference for convenient and easily digestible supplements has propelled the nutraceutical segment, which is a significant driver of the softgel capsules market. With an increasing emphasis on healthy lifestyles and wellness, the demand for high-quality dietary supplements continues to soar, positioning softgel capsules as a preferred choice.

Innovations in manufacturing technologies have also played a pivotal role in the industry’s growth. Manufacturers are now able to produce softgel capsules with various colors, shapes, and sizes, catering to consumer preferences and enhancing product branding and appeal. Moreover, the industry is embracing sustainable and vegan-friendly options, aligning with the growing demand for eco-conscious and ethically sourced products.

According to a recent report by MarketsandMarkets™, the global softgel capsules market was estimated to be worth $1.1 billion in 2023 and is projected to reach $1.5 billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period. This significant growth is attributed to the numerous benefits of softgel capsules, the rising demand for dietary supplements and nutraceuticals, and the increasing preference for naturally sourced ingredients.

The softgel capsules market spans diverse sectors, including pharmaceuticals, dietary supplements, and cosmetics, with the nutraceutical and dietary supplement industry segment leading the charge in 2022. Geographically, the Asia Pacific region is anticipated to be the fastest-growing market, driven by factors such as large populations, rising health concerns, higher incomes, and government initiatives supporting the pharmaceutical industry.

As the softgel capsules industry continues to evolve, personalization and customization present significant opportunities for manufacturers to meet the unique needs of consumers. However, rising prices of raw materials remain a challenge that must be addressed to sustain long-term growth and profitability.

With its multitude of advantages, including enhanced bioavailability, accurate dosage delivery, easy swallowing, and extended shelf life, the softgel capsules market is poised to revolutionize the way we consume and deliver a wide range of products, from pharmaceuticals to supplements and beyond.

The global home healthcare market is poised to achieve significant growth, expected to soar to USD 383.0 Billion by 2028 from USD 250.0 Billion in 2023, indicating a robust CAGR of 8.9% during the forecast period. This growth trajectory is primarily propelled by the expanding elderly population and the increasing prevalence of chronic ailments.

Key Market Players:

Leading players in the market include Fresenius SE & Co. KGaA (Germany), Abbott (US), GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), ResMed, Inc. (US), among others. These key industry participants are strategically employing various tactics to steer the global growth trajectory of the home healthcare sector.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=696

Fresenius SE & Co. KGaA (Germany):

Fresenius SE & Co. KGaA (Germany) secured the top position in the home healthcare market in 2022, commanding a 4.7% market share. The company has cemented its leading status through robust distribution networks spanning North America, Europe, Latin America, Asia Pacific, and Africa. Fresenius boasts both direct and indirect distribution channels globally and pursues a blend of organic and inorganic growth strategies. Notably, the company expanded its home hemodialysis product offerings in Europe, the Middle East, and Africa in May 2020. Additionally, in August 2022, Fresenius acquired InterWell Health Brand (US), augmenting its expertise in kidney care value-based contracting and performance.

Abbott (US):

Abbott (US) captured a 3.9% share of the home healthcare market in 2022, leveraging its expanding global sales and distribution network. The company prioritizes research and development endeavors to develop and produce innovative products, enhancing its competitive edge. Abbott’s substantial investments in R&D fortify its product portfolio and distribution strategies, positioning it favorably for future growth. Moreover, Abbott pursues strategic acquisitions to bolster its market presence, exemplified by its collaboration with Insulet Corporation (US) in June 2020 to integrate Abbott’s CGM technology with Insulet’s Omnipod Horizon Automated Insulin Delivery System, providing tailored automated insulin delivery and care solutions for individuals with diabetes.

Global Home Healthcare Manufacturers:

Prominent manufacturers in the home healthcare industry include Philips Healthcare (Netherlands), Medtronic plc (Ireland), Omron Healthcare, Inc. (Japan), Fisher & Paykel Healthcare Limited (New Zealand), Bayer AG (Germany), Roche Diagnostics (Switzerland), Becton, Dickinson and Company (BD) (United States), among others. These companies specialize in offering a diverse array of home healthcare products and solutions, spanning medical devices, monitoring equipment, diagnostic tools, and other tailored healthcare products for home use.

Philips Healthcare (Netherlands):

Philips Healthcare leads the global home healthcare solutions market, offering an extensive range of medical devices and equipment designed to facilitate at-home health management. From sleep apnea therapy devices to remote patient monitoring solutions, Philips’ innovative offerings empower individuals to monitor and manage their health conditions conveniently.

Medtronic plc (Ireland):

Renowned for its medical technologies and solutions, Medtronic plc provides a wide array of home healthcare products aimed at enhancing patient outcomes and quality of life. With a focus on innovation and patient-centricity, Medtronic’s portfolio includes insulin pumps, continuous glucose monitoring systems, and other devices tailored for managing chronic conditions at home.

Omron Healthcare, Inc. (Japan):

A leading manufacturer of home healthcare devices, Omron Healthcare, Inc. emphasizes wellness promotion and disease prevention. Its product lineup encompasses blood pressure monitors, nebulizers, thermometers, and activity trackers, empowering individuals to monitor vital health parameters and make informed decisions about their health.

Fisher & Paykel Healthcare Limited (New Zealand):

Specializing in respiratory care products and sleep apnea therapy devices, Fisher & Paykel Healthcare Limited prioritizes patient comfort and compliance. Its offerings include humidification systems, nasal masks, and CPAP devices, tailored to meet diverse patient needs worldwide.

Bayer AG (Germany), Roche Diagnostics (Switzerland), Becton, Dickinson and Company (BD) (United States):

These global healthcare giants offer a wide range of consumer health products and medical devices for home use, spanning blood glucose meters, self-testing kits, insulin syringes, pen needles, lancets, and more, empowering individuals to manage their health conditions effectively at home.

According to a new report by MarketsandMarkets™ – Oligonucleotide Synthesis Market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach $19.7 billion by 2029, growing at a CAGR of 17.5% from 2024 to 2029.

One of the key factors driving the market growth is the growing acceptance of alternate therapies such as oligonucleotide-based therapies for the treatment of neurological and rare The incorporation of synthesized oligonucleotides to treat various diseases also supports market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350

Probes are an important subsegment in the market for synthesized oligonucleotides. The segment accounted for the second-largest market share of the synthesized oligonucleotide market. This is due to high specificity and sensitivity of probes allowing their use in genetic research, pathogen detection, clinical diagnostics, and the study of gene expression patterns, offering insights into diverse biological processes and disease mechanisms. Techniques such as fluorescence in situ hybridization (FISH) utilize these probes for the detection of various genetic abnormalities that the root cause of several birth defects, neurological conditions and cancers among others.

By end user, hospitals accounted for the largest share of the oligonucleotide synthesis market in 2023. Growth in this market is largely driven by the significant number of FDA-approvals for oligonucleotide-based drugs especially antisense oligonucleotide drugs for rare and neurological diseases, increasing awareness towards alternative therapies and growing health-care spending. Ongoing research to develop oligonucleotide-based drugs for more common diseases such as cardiovascular diseases, supported by availability of reimbursement policies in developed economies are aiding this segment’s growth.

In 2023, PCR accounted for the largest share of the research application subsegment of the oligonucleotide synthesis market. PCR technologies such as real-time PCR or quantitative PCR (qPCR) used for both qualitative and quantitative analysis in the fields of molecular diagnostics, medicine, microbiology, and forensic biology are driving end-user demand. These PCR applications utilize sequence-specific primers, thus boosting the market for oligos (which are used as probes and primers) in the PCR market.

The North America region is expected to show the highest CAGR of the oligonucleotide synthesis market. The growing investments in research and development by major pharmaceutical & biotechnology companies, increasing application of oligonucleotides in pharmaceutical drug research, and growing public & private sector investments in genomics and related technologies are expected to aid market growth in the North America.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=200829350

Oligonucleotide Synthesis Market Dynamics:

Drivers:

1. Increasing use of synthesized oligos in therapeutic and diagnostic applications
2. Technological advancements
3. Growing government investments in life science research and synthetic biology
4. Growing focus on precision/personalized medicine

Restraints:

1. Complexities associated with therapeutic oligonucleotides

Opportunities:

1. Increasing R&D investments by key players in emerging economies

Challenge:

1. Lack of standard regulations
2. Delivery of oligonucleotide drugs to specific targets

Key Market Players of Oligonucleotide Synthesis Industry:

Some leading players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai Lifesciences holdings, Inc. (US), Azenta, Inc. (US), Twist Bioscience Corporation (US) and Genscript Biotech Corporation (US). Major players in the oligonucleotide therapeutics market are Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Astrazeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US) and Novartis AG (Switzerland).

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side – 30%
• By Designation: Managers- 45%, CXOs, and Director level – 30%, and Executives – 25%
• By Region: North America -35%, Europe – 25%, Asia-Pacific -15%, Latin America -10%, Middle East- 10%, Africa- 5%

Recent Developments of Oligonucleotide Synthesis Industry:

• In November 2023, LCG Biosearch Technologies, a business unit of LGC Limited, acquired PolyDesign to enhance its oligonucleotide synthesis capabilities using PolyDesign’s frit technology.
• In October 2023, Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, opened its therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This facility will produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligos.

Content Source: https://www.prnewswire.com/news-releases/oligonucleotide-synthesis-market-worth-19-7-billion–marketsandmarkets-302128509.html

According to a new report by MarketsandMarkets™ – Healthcare Analytical Testing Services Market in terms of revenue was estimated to be worth $7.4 billion in 2024 and is poised to reach $12.6 billion by 2029, growing at a CAGR of 11.2% from 2024 to 2029.

The expansion of the healthcare analytical testing services market is driven by growing demand across various industries seeking quality assurance and compliance with regulations. Challenges in refining accurate analytical techniques create openings for service providers, while government efforts foster investment and creativity. These dynamics stimulate market growth worldwide, along with trends like outsourcing driven by cost considerations and advancements in pharmaceuticals. Additionally, venturing into new markets increases the demand for tailored testing, further spurring the requirement for Healthcare Analytical Testing Services.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=108923833

The Healthcare Analytical Testing Services market is diversified based on the types of services offered, encompassing cell-based assays, virology testing, biomarker testing, immunogenicity and neutralizing antibody testing, pharmacokinetic testing, and various other bio–Healthcare Analytical Testing Services. Among these, cell-based assays emerged as the dominant segment in 2023. This dominance can be attributed to the increasing utilization of cell-based assays in high-throughput screening processes. Unlike biochemical assays, cell-based assays offer the advantage of providing biologically relevant in vivo information, thereby expediting the drug discovery process. This trend underscores the growing importance of cell-based assays in meeting the demands of pharmaceutical and biotechnology companies for efficient and effective analytical testing

The Healthcare Analytical Testing Services market caters to various end users, including pharmaceutical & biopharmaceutical companies, medical device manufacturers, forensic laboratories, hospitals and clinics, as well as cosmetics and nutraceutical companies. In 2023, pharmaceutical & biopharmaceutical companies emerged as the leading end users, holding the largest market share. This dominance is primarily due to the increasing trend among these companies to outsource their analytical testing needs. By outsourcing, pharmaceutical and biopharmaceutical firms can optimize their resources, streamline operations, and focus more on their core competencies such as research, development, and production. This strategic approach allows them to enhance efficiency, maintain regulatory compliance, and ultimately improve profit margins. As a result, the demand for Healthcare Analytical Testing Services from pharmaceutical and biopharmaceutical companies continues to grow, driving the expansion of this market segment.

The Healthcare Analytical Testing Services market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these regions, North America stands out as the largest contributor to market share. This dominance is primarily driven by the burgeoning presence of biopharmaceutical and pharmaceutical companies, particularly in the United States. The US, being a hub for innovation and research in the healthcare sector, attracts significant investments and fosters the development of advanced analytical testing solutions. Furthermore, the region benefits from the presence of well-established market players with extensive expertise and infrastructure. Their robust capabilities and technological advancements contribute significantly to the growth and sophistication of the Healthcare Analytical Testing Services market in North America. Overall, the region’s favorable regulatory environment, coupled with its focus on quality assurance and compliance, further solidifies its leading position in the global market landscape.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=108923833

Healthcare Analytical Testing Services Market Dynamics:

Drivers:

1. Changing regulatory landscape and the increasing complexity of products to drive the market
2. Rising number of Clinical Trials

Restraints:

1. Lack of skilled professionals

Opportunities:

1. Harnessing Government Support and Technology Advancements in Healthcare analytical testing services

Challenge:

1. Need for improvement to the sensitivity of analytical testing

Key Market Players of Healthcare Analytical Testing Services Industry:

The prominent players in the global Healthcare Analytical Testing Services market include Eurofins Scientific (Luxembourg), , Thermo Fisher Scientific, Inc. (US), Pace Analytical Services LLC (US), Intertek Group plc (UK), IQVIA Inc. (US), Merck KGaA (Germany), Source BioScience (UK), Almac Group (UK), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK), ICON Plc (Ireland), Frontage Laboratories, Inc. (US), STERIS Plc (US), Sartorius AG (Germany), ALS Life Science (US), Syneos Health, INC (US), Medpace Holdings, Inc. (US), LGC Limited (UK), Parexel International Corporation (US), Celerion (US). Pharmaron (China), and BioAgilytix Labs (US).

The break-down of primary participants is as mentioned below:

• By Company Type – Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
• By Designation – C-level: 42%, Director-level: 31%, and Others: 27%
• By Region – North America: 32%, Europe: 32%, Asia Pacific: 26%, ROW-10%

Research Insights: https://www.marketsandmarkets.com/ResearchInsight/healthcare-analytical-testing-services-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/healthcare-analytical-testing-services.asp

According to a new report by MarketsandMarkets™ – Clinical Communication & Collaboration Market in terms of revenue was estimated to be worth $2.6 billion in 2024 and is poised to reach $4.8 billion by 2029, growing at a CAGR of 13.2% from 2024 to 2029.

The growth in the clinical communication and collaboration market is driven by high prevalence of chronic diseases, rising prominence of big data and mHelath tools, and stringent regulatory requirements and industry standards. Moreover, transition towards value-based care and population health management further increases the significance of clinical communication and collaboration solutions. Thus, the the growing emphasis on interoperability and data exchange within healthcare ecosystems is expected to drive the integration of clinical communication and collaboration market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=118830286

On the basis component, the Clinical Communication and Collaboration market is segmented into hardware, software and services segment. The software segment accounted for the largest share of the component segment in 2023. The software segment comprises of clinical alerting & notification, physician & nurse scheduling systems, telehealth platform, collaborative care platforms. The clinical alerting & notification segment held the largest market share in the software segment. These systems plays a pivotal role in enhancing patient safety, as it reduces response times, and improves clinical decision-making. Moreover, the increasing focus on care coordination and continuity across healthcare settings has propelled the demand for robust clinical alerting and notification solutions. Owing to the many benefits of the software solutions, several healthcare providers are increasingly adopting these solutions for smooth workflows and enhanced quality care.

Based on application, the Clinical Communication and Collaboration market is segmented into lab & radiology communication, nurse communication, patient communication & emergency alerts, physician communication. The physician communication segment held the largest market in 2023 due to its pivotal role in facilitating effective care delivery and enhancing care coordination. Moreover, the unique communication needs of physicians, including the requirement for secure and confidential communication channels, further highlights the importance of dedicated physician communication solutions within the clinical communication and collaboration market. These solutions offer encrypted messaging, secure voice and video calling, and other advanced features tailored to the specific requirements of healthcare providers, enabling them to communicate effectively while adhering to stringent privacy and security regulations.

Based on end users, the Clinical Communication and Collaboration market is segmented into hospitals & clinics, ambulatory surgical centers, long-term care facilities, nursing centers and other end-users which includes maternity care centers & fertility centers, and trauma and emergency care centers. The hospitals & clinics held the largest share among the end-users in 2023. From emergency departments and operating rooms to inpatient units and outpatient clinics, healthcare providers in hospitals and clinics rely heavily on effective communication channels to coordinate care plans, consult with colleagues, and ensure continuity of care for patients. As healthcare organizations continue to prioritize communication solutions that enhances care coordination, streamlines workflows, and support remote care delivery, hospitals and clinics are poised to remain key drivers of innovation and growth in the clinical communication and collaboration market.

The Clinical Communication and Collaboration market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2023, North America accounted for the largest share of the Clinical Communication and Collaboration market. This region’s dominance is due to highly developed healthcare infrastructure characterized by advanced technology adoption, robust regulatory frameworks, and a strong emphasis on patient-centric care delivery. Moreover, the presence of key market players such as Avaya LLC (US), Oracle (US), Cisco Systems, Inc. (US), Microsoft Corporation (US) among others are a key factor contributing to the growth of the region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=118830286

Key Market Players of Clinical Communication & Collaboration Industry:

Prominent players in the Clinical Communication and Collaboration market include Avaya LLC (US), Oracle (US), Cisco Systems, Inc. (US), Microsoft Corporation (US), Baxter International (Hillrom) (US), symplr (US), NEC Corporation (Japan), Spok Inc. (US), Vocera Communications (Stryker) (US), Ascom Holding AG (Switzerland), Everbridge (US), Hidden Brains InfoTech. (India), Imprivata, Inc. (US), CommuniCare Technology, Inc. d/b/a Pulsara (US), Mobile Heartbeat (C-HCA, Inc.) (US), OnPage. (US), HARRIS ONPOINT (US), Jive Software, LLC (US), TigerConnect (US), JCT Healthcare Pty Ltd. (Australia), Amplion (US), AndorHealth (US), PerfectServe, Inc. (US), QliqSOFT, Inc. (US), and Connexall, GlobeStar Systems Inc. (Canada).

Research Insights: https://www.marketsandmarkets.com/ResearchInsight/clinical-communication-collaboration-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/clinical-communication-collaboration.asp

According to a new report by MarketsandMarkets – Sleep Apnea Oral Appliances Market in terms of revenue was estimated to be worth $0.4 billion in 2023 and is poised to reach $0.9 billion by 2028, growing at a CAGR of 15.2% from 2023 to 2028. The growth of this market is majorly driven by the high risk of growing awarrness and diagnosis of sleep apnea among patients and healthcare professionals. Furthermore, the poor compliance associated with CPAP is expected to drive the growth of the sleep apnea oral appliances market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105423877

Mandibular advancement devices force the lower jaw forward and downwards slightly, which keeps the airway open. The device helps treat OSA by offering maximum anterior tongue space along with the retention of teeth movement. This segment is expected to dominate the global sleep apnea oral appliances market during the forecast period, driven by a rising patient preference for non-CPAP solutions due comfort and ease of use.

By end user, the global sleep apnea oral appliances market is broadly segmented into home care settings/individuals, hospitals, and dental clinics. The large share of this segment can be attributed to factors such as the increasing number of sleep centers globally, the rise of number of sleep care devices for homecare settings offered by leading players.

Based on the region, the sleep apnea oral appliances market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American market is driven by high prevalence and diagnosis of sleep apnea in the region. Europe is the second-largest market for the sleep apnea oral appliances market due to the growing aging population in the region. Asia Pacific will observe high growth during the forecast period with its growing healthcare expenditure with improving accessibility to sleep clinics and treatment for sleep apnea in the region’s countries.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=105423877

Sleep Apnea Oral Appliances Market Dynamics:

Drivers:

1. Large pool of undiagnosed sleep apnea patients

Restraints:

1. Associated risks of oral appliances for obstructive sleep apnea treatment

Opportunities:

1. Poor compliance associated with CPAP

Challenge:

1. Expenses associated with customization of oral appliances

Key Market Players of Sleep Apnea Oral Appliances Industry:

Major players in the sleep apnea oral appliances market include SonmoMed (Australia), resMed (US), Whole You, Inc. (US), ProSomnus Sleep Technologies (US), and Vivos Therapeutics, Inc. (US).

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (40%), Tier 2 (50%), and Tier 3 (10%)
• By Designation: C-level (48%), Director-level (37%), and Others (15%)
• By Region: North America (56%), Europe (20%), Asia- Pacific (17%), and Rest of the World (7%)

Sleep Apnea Oral Appliances Market Recent Developments:

• In 2023, Vivos Therapeutics, Inc. (US) DNA appliance was granted 510(k) clearance from the U.S. Food & Drug Administration (or FDA) as a Class II medical device in December 2022 for the treatment of snoring and mild to moderate OSA in adults.
• In 2022, ResMed (US) acquired the German-based clinical, financial, and operational solutions provider MEDIFOX DAN (Germany) to drive leadership in out-of-hospital software solutions.
• In 2021, SomoMed (Australia) conducted SomSUMMIT ’21, which aimed to enhance research, education, and awareness of oral appliance therapy as a primary solution to successful OSA treatment.

According to a new report by MarketsandMarkets™. – Endoscopy Equipment Market in terms of revenue was estimated to be worth $32.3 billion in 2024 and is poised to reach $46.2 billion by 2029, growing at a CAGR of 7.4% from 2024 to 2029.

The growth in this market is primarily driven by factors such as increasing prevalence of gastrointestinal diseases, rising demand for minimally invasive surgeries, technological advancements leading to enhanced imaging and procedural capabilities, expanding healthcare infrastructure, and growing awareness about early disease diagnosis and treatment.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=689

In the forecast period, the endoscopes segment dominated the global endoscopy equipment market. This significant share can be credited to the increasing favouritism of minimally invasive procedures by both patients and healthcare professionals, along with the elevated uptake of such equipment by end users. Moreover, continuous advancements in endoscopy technologies contribute to the segment’s substantial presence in the market.

Based on application, the obstetrics/gynecology endoscopy segment of the endoscopy equipment market accounted the third largest market share in the forecast period. This growth subjected to the rising incidence of gynaecological conditions like endometriosis, uterine fibroids. Technological improvements in visualization systems and endoscopes, accessories tools like grasping tools are driving the growth of the gynecology endoscopy segment as well.

Ambulatory surgery centers/clinics secure the second-largest market share in the endoscopy equipment market. This largest share comes from the increasing trend towards outpatient procedures due to their convenience and cost-effectiveness. Additionally, the rising demand for minimally invasive surgeries in these settings drives the adoption of advanced endoscopy equipment. As ambulatory surgery centers continue to grow in popularity, the demand for endoscopy equipment in these facilities is expected to witness steady growth in the foreseeable future.

Europe to possess the second largest market share in the endoscopy equipment market in the forecast period due to its rising investments towards medical technology, high adoption rates of advanced medical technologies, and increasing prevalence of gastrointestinal diseases. These factors drive demand for endoscopy equipment, positioning Europe as one of the leading market regions.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=689

Endoscopy Equipment Market Dynamics:

Drivers:

1. Growing focus of hospitals to invest in technologically advanced endoscopy instruments and expand endoscopy units

Restraints:

1. High overhead costs of endoscopy procedures with limited reimbursement in developing countries

Opportunities:

1. Booming healthcare sector in developing economies

Challenge:

1. Shortage of trained physicians and endoscopicts

Key Market Players of Endoscopy Equipment Industry:

Prominent players in the endoscopy equipment market include Olympus Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Boston Scientific Corporation (US), JOHNSON & JOHNSON (US), Stryker Corporation (US), Medtronic, plc (Ireland), Fujifilm Holdings Corporation (Japan), HOYA Corporation (Japan), Nipro Corporation (Japan), Smith & Nephew plc (UK), Intuitive Surgical, Inc. (US)

A breakdown of the primary participants (supply side) for the endoscopy equipment market referred to for this report is provided below:

• By Company Type: Tier 1–35%, Tier 2–20%, and Tier 3–45%
• By Designation: C-level–45%, Director Level–25%, and Others–30%
• By Region: North America–36%, Europe–26%, Asia Pacific–21%, Latin America-10%, and Middle East & Africa_ 7%

Recent Developments of Endoscopy Equipment Industry:

• In November 2023, Olympus Corporation launched the EVIS X1, an advanced endoscopy system in the existing product portfolio of the company.
• In September 2023, Stryker launched, 1788, a minimally invasive surgical camera, offering more vibrant image with balanced lighting.
• In January 2022, The Johnson & Johnson Medical Devices Companies (JJMDC) collaborated with Microsoft Corporation Inc, (US) to enable and expand JJMDC’s secure and compliant digital surgery ecosystem.

According to a new report by MarketsandMarkets™ – Companion Diagnostics Market in terms of revenue was estimated to be worth $7.5 billion in 2024 and is poised to reach $13.6 billion by 2029, growing at a CAGR of 12.6% from 2024 to 2029.

The global companion diagnostics market is poised for significant growth in the near future, driven by the increasing incidence of cancers worldwide. This rise in cancer cases is fueling the demand for more accurate and personalized treatment options. Companion diagnostics play a crucial role in this scenario by helping to select appropriate targeted therapies for patients based on their genetic makeup and likely response. This personalized approach is expected to improve treatment outcomes while reducing adverse reactions to unsuited medicines. Additionally, the approvals of many targeted oncology drugs, along with complementary companion diagnostics, by regulatory agencies are expected to further propel the market growth. Emerging economies like China, Japan, and India are presenting attractive opportunities for companies operating in this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681

Based on product & service, the companion diagnostics market is segmented into assays, kits & reagents, instruments/systems and software & services. The dominance of the assays, kits & reagents segment in 2023 can be attributed primarily to the broad range of available products and the rapidly increasing utilization of assays and kits across various therapeutic areas.

Based on technology, the companion diagnostics market is categorized into polymerase chain reaction (PCR), in situ hybridization (ISH), next-generation sequencing (NGS), immunohistochemistry (IHC), and other technologies. In 2023, the PCR segment held the largest portion of the companion diagnostics market. PCR has become essential in companion diagnostics, especially in the interpretive practice by pharmaceutical companies related to oncology drugs, due to its reliability, sensitivity, and ability to obtain quantitative results. Its extensive range of applications and established market presence give it a significant position in the field.

Based on indication, the companion diagnostics market is segmented into cancer, cardiovascular diseases (CVDs), neurological diseases, infectious diseases, and other indications (inflammatory and inherited diseases, among others). In 2023, the cancer segment held the largest share of the companion diagnostics market. This can be attributed to factors such as the expanding role of companion diagnostics in personalized medicine treatments for cancer, as well as the growing importance of biomarkers in cancer diagnosis.

Based on sample type, the companion diagnostics market is segmented into liquid, blood, and other sample types. In 2023, the tissue sample segment accounted for the largest share of the companion diagnostics market. Tissue samples are often preferred in companion diagnostics for their ability to provide a direct analysis of the tumor, offering a comprehensive view of genetic mutations and biomarkers for more accurate and personalized treatment decisions.

Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users (including physician & hospital laboratories and academic medical centers). The pharmaceutical & biotechnology companies segment held the largest share of the companion diagnostics market in 2023. This is primarily driven by factors such as the rising utilization of companion diagnostics in drug development and the growing significance of companion diagnostic biomarkers.

The global companion diagnostics market is divided into six key regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2023, North America held the largest portion of the companion diagnostics market. The growth of the North American companion diagnostics market can be credited to several factors, including the significant presence of leading companion diagnostics vendors and national clinical laboratories. Additionally, the easy access to technologically advanced devices and instruments, along with the highly developed healthcare systems in the US and Canada, contributed to the market’s expansion in this region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=155571681

Key Market Players of Companion Diagnostics Industry:

The major players in this market are F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US), Abbott (US), Almac Group (UK), Danaher (US), Illumina, Inc. (US), bioMérieux (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), ARUP Laboratories (UK), Abnova Corporation (Taiwan), Guardant Health (US), ICON Plc (Ireland), BioGenex (US), Invivoscribe, Inc. (US), ArcherDX, Inc. (Integrated DNA Technologies, Inc.) (US), NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China), Uniogen (Abacus Diagnostica) (Finland), Asuragen, Inc. (Bio-Techne) (US), NG Biotech (France), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).